Related Experiment Videos
[Clinical studies of T-1982 (cefbuperazone) in the field of pediatrics]
Insights
Cefbuperazone (T-1982) shows excellent antibacterial activity against Gram-negative bacilli and achieved a 100% efficacy rate in children with bacterial infections. This new cephamycin antibiotic is considered a useful treatment option.
Area of Science:
- Medical Microbiology
- Pediatric Infectious Diseases
- Pharmacology
Background:
- Bacterial infections in children necessitate effective and safe antibiotic treatments.
- Cephamycin antibiotics offer broad-spectrum activity against various pathogens.
- The development of new antimicrobial agents is crucial for combating resistance.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of T-1982 (cefbuperazone) in pediatric patients.
- To determine the in vitro antibacterial spectrum and potency of T-1982 against clinically relevant bacteria.
- To assess the pharmacokinetic and pharmacodynamic properties of T-1982 in children.
Main Methods:
- Clinical trials involving 25 children diagnosed with bacterial infections.
- In vitro susceptibility testing of T-1982 against a panel of Gram-negative and Gram-positive bacteria.
- Monitoring of clinical outcomes, including symptom resolution and microbiological eradication.
- Assessment of adverse events and laboratory parameters throughout the treatment period.
Main Results:
- T-1982 demonstrated potent in vitro activity against Gram-negative bacilli, with MICs < 0.39 µg/ml for E. coli and K. oxytoca, and < 1.56 µg/ml for H. influenzae.
- Clinical efficacy was observed in all 24 evaluated cases, with an efficacy rate of 100%.
- Adverse effects were generally mild and transient, including slight elevations in liver enzymes (GOT, GPT), eosinophilia, mild thrombocytopenia, and rash.
Conclusions:
- Cefbuperazone (T-1982) is a highly effective antibiotic against Gram-negative bacterial infections in children.
- The safety profile of T-1982 is favorable, with mostly mild and transient side effects.
- T-1982 represents a promising therapeutic option for treating bacterial infections in pediatric populations.
Abstract:
T-1982 (cefbuperazone), a new cephamycin antibiotic, was clinically and bacteriologically studied in 25 children with bacterial infections. The following results were obtained. 1. The antibacterial activity of T-1982 was determined against clinically isolated bacteria. T-1982 demonstrated excellent activity against Gram-negative bacilli, the MICs being less than 0.39 microgram/ml against E. coli and K. oxytoca, less than 1.56 microgram/ml against H. influenzae. 2. Clinical response was excellent or good in all 24 cases evaluated. The efficacy rate was 100%. 3. As for side effects associated with T-1982, slight and transient elevation of GOT, GPT and eosinophil, slight decrease of platelet and eruption were observed. From these results, T-1982 is considered to be a useful antibiotic for treating bacterial infections in children.